Delivery Order SPE2DB24D9113-SPE2DB25FEQDJ
- Not listed
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a $8,622.72 firm fixed-price delivery order by the Defense Logistics Agency (DLA) on September 3, 2025, for the supply of Xtandi 40 mg capsules (120-count units). The contract, which carries no set-aside designation, is set for ultimate completion by September 4, 2025, and represents a delivery order issued under DMS Pharmaceutical Group's substantial Indefinite...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $8,339.18 by the Defense Logistics Agency on July 21, 2025, for the supply of Xtandi 80 mg tablets (60-count units). This delivery order was issued without a set-aside designation and is scheduled for completion by July 22, 2025, with performance taking place at the contractor's Park Ridge facility. The award represents a...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order on July 28, 2025, valued at $4,169.59 for the supply of Xtandi 40 mg tablets (120 count) to the Defense Logistics Agency (DLA). This firm fixed-price delivery order, which must be completed by July 29, 2025, carries no set-aside designation. The award leverages DMS Pharmaceutical Group's existing Indefinite Delivery Contract (IDC) with the DLA under...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order on July 30, 2025, for 120 tablets of Xtandi 40 mg with a ceiling value of $8,339.18. This firm fixed-price delivery order, which has an ultimate completion date of July 31, 2025, was issued without a set-aside designation and is funded through the Defense Logistics Agency's Medical Supply Chain. The award represents a single delivery order under DMS...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $4,169.59 by the Defense Logistics Agency (DLA) on August 25, 2025, for the supply of Xtandi 80 mg tablets (60-count packages). The award carries a firm fixed-price structure with an ultimate completion date of August 26, 2025. This delivery order was issued without a set-aside designation, allowing DMS Pharmaceutical Group to compete on an...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, has been awarded a firm fixed-price delivery order valued at $4,169.59 by the Defense Logistics Agency for the supply of Xtandi 80 mg tablets (60-count units). The award, issued on September 3, 2025, with an ultimate completion date of September 4, 2025, carries no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order by the Defense Logistics Agency (DLA) on September 10, 2025, for the supply of Xtandi 40 mg capsules (120-count units). The contract ceiling value is $38,376.87, with an ultimate completion date of September 11, 2025. This delivery order carries no set-aside designation and represents a direct fulfillment order under DMS Pharmaceutical...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $8,339.18 by the Defense Logistics Agency (DLA) on August 11, 2025, for the supply of Xtandi 80 mg tablets (60-count units). The contract utilizes a firm fixed-price structure with no set-aside designation and is scheduled for completion by August 12, 2025. This delivery order falls under DMS Pharmaceutical Group's larger Indefinite...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order on August 11, 2025, by the Defense Logistics Agency (DLA) for Xtandi 80 mg tablets (60-count packages) with a ceiling value of $12,508.77. This firm fixed-price delivery order, with an ultimate completion date of August 12, 2025, was issued without a set-aside designation. The contract represents a discrete fulfillment under DMS Pharmaceutical...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $8,339.18 by the Defense Logistics Agency (DLA) on August 14, 2025. The contract calls for the delivery of Xtandi 80 mg tablets (60-count supply), an oncology medication used in prostate cancer treatment. This delivery order carries an ultimate completion date of August 15, 2025, and was awarded without a set-aside...
- SPE2DB24D9113Indefinite Delivery Contract
- SPE2DB24D9113-SPE2DB25FEQDJDelivery Order
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order by the Defense Logistics Agency (DLA) on September 9, 2025, for the supply of Xtandi 40 mg tablets (120-count units) with a ceiling value of $8,339.18. This firm fixed-price delivery order, which is scheduled for completion by September 10, 2025, represents a tactical execution under DMS Pharmaceutical Group's larger Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program. The IDC, valued at $499,999,999 and valid through November 2026, authorizes the agency to issue delivery orders for a comprehensive range of pharmaceutical products supporting medical supply needs across Department of Defense healthcare facilities worldwide. Xtandi, an oncology medication used in the treatment of prostate cancer, exemplifies the specialized pharmaceutical products that DMS Pharmaceutical Group regularly supplies to federal healthcare systems. The award was made without set-aside designation, demonstrating the company's competitive positioning in federal procurement markets. As a critical supplier in the defense pharmaceutical supply chain since its SAM.gov registration in 2001, DMS Pharmaceutical Group maintains consistent delivery capabilities across branded and generic prescription drugs, biologics, and medical consumables to military health facilities nationwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.3k | 9/9/25 |